VEGFA and neoplasm: The immunosuppressive activity of VEGF-A, in addition to the direct effects of that cytokine on tumor vasculature and melanoma growth and metastasis, might therefore underlie the association of high serum levels of VEGF-A with a poor clinical response to BRAFi and MEKi.